The study showed administration of the PCSK9 inhibitors to statin-treated patients with coronary artery disease produced significantly lower rate of CAC progression, and the results might be partially related to the Lp(a) lowering effects with PCSK9 inhibitors. This evidence concerns the gene PCSK9 and coronary artery disorder.